Cell binding and internalisation of oligonucleotides

S.T.P. Pharma Sciences

Volumn 11, Issue 1, 2001, Pages 75-82

  Le Doan, T ^a  

^a INSTITUTE FOR INTEGRATIVE BIOLOGY OF THE CELL I2BC   (France)

Author keywords

Antisense; Cell binding; Cellular traffic; Internalisation; Oligonucleotides

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL SURFACE PROTEIN; OLIGONUCLEOTIDE;

CELL ADHESION; CELL COMPARTMENTALIZATION; CELL INTERACTION; CELL MEMBRANE PERMEABILITY; CELLULAR DISTRIBUTION; CHEMICAL STRUCTURE; HUMAN; INTERNALIZATION; MOLECULAR SIZE; NONHUMAN; REVIEW;

EID: 0035128824     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Antisense therapeutics: Is it as simple as complementary base recognition?
2. An overview of progress in antisense therapeutics
3. In vivo studies with antisense oligonucleotides
4. Vitravene, another piece in the mosaic
5. Transport of oligonucleotides across natural and model membranes
6. Cellular uptake and intracellular fate of antisense oligonucleotides
7. Characterisation of oligonucleotide transport into living cells
8. Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors?
9. Binding of oligonucleotides to cell membranes at acidic pH
10. Human T-cell leukaemia virus type I tax transformation is associated with increased uptake of oligonucleotides in vitro and in vivo
11. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides
12. Bovine serum albumin is a major oligonucleotide-binding protein found on the surface of cultured cells
13. The Influence of polarised ephitelial (Caco-2) cell differentiation on the cellular binding of phosphodiester and phosphorothioate oligonucleotides
14. Interaction of oligodeoxynucteotides with mammalian cells
15. Mac-1 (CD 11 b/CD18) is an oligodeoxynucleotide-binding protein
16. Interaction of human plasma membrane proteins and oligodeoxynucleotides
17. Identification and characterisation of a cell membrane nucleic acid channel
18. Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors
19. Co-administration of polyanions with a phosphorothioate oligodeoxynucleotide (CGP 69846A): A role for the scavenger receptor in its in vivo disposition
20. Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes
21. Identification, purification and partial characterisation of an oligonucleotide receptor in membranes of Hep G2 cells
22. Nucleosomes and DNA bind to specific cell-surface molecules on murine cells and induce cytokine production
23. Identification of DNA-binding proteins on human umbilical vein endothelial cell plasma membrane
24. Cell membrane DNA: A new target for psoralen photo-adduct formation
25. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides
26. Does antisense exist?
27. Patterns of intracellular compartmentalisation, trafficking and acidification of 5'fluorescein labelled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells
28. Cellular uptake mechanism for oligonucleotides: Involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15
29. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells
30. Cellular pharmacology of phosphorothioate homo-oligodeoxynucleotides in human cells
31. Sequence dependency of the internalisation and distribution of phosphorothioate oligonucleotides in vascular smooth muscle cells
32. Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs
33. Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible
34. Influence of base composition on membrane binding and cellular uptake of 10-merphosphorothioate oligonucleotides in Chinese hamster ovary (CHRC5) cells
35. Dynamics of the internalisation of phosphodiester oligodeoxynucleotides in HL60 cells
36. Liposomes as a drug delivery system for antisense oligonucleotides
37. Antisense c-myc oligonucleotide cellular uptake and activity
38. Calcium-dependent oligonucleotide cellular uptake
39. Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes
40. Caveolae: Where incoming and outgoing messengers meet
41. Stimulation of calcium influx in HL60 cells by cholesteryl-modified homopolymer oligodeoxynucleotides
42. Rapid nuclear accumulation of injected oligodeoxyribonucleotides
43. Intracellular distribution of microinjected antisense oligonucleotides
44. Intracellular disposition and metabolism of fluorescently-labelled unmodified oligonucleotides microinjected into mammalian cells
45. Parameters controlling topical delivery of oligonucleotides by electroporation
46. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilisation of human leukaemia cells with streptolysin O
47. Reversible permeabilisation. A novel technique for the intracellular introduction of antisense oligonucleotides into intact smooth muscle
48. Fluorescence microscopic comparison of the binding of phosphodiester and phosphorothioate (antisense) oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum, and the nuclear interior
49. Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide
50. Natural and Phosphorothioate-modified oligodeoxyribonucleotides exhibit a non-random cellular distribution
51. Characteristics of oligonucleotide uptake in human keratinocyte cultures
52. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes
53. Association of antisense oligonucleotides with lipoproteins prolongs the half-life and modifies the tissue distribution
54. Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy
55. Intracellular routing and inhibitory activity of oligonucleopeptides containing a KDEL motif
56. Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis
57. Oligonucleotide-poly(LLysine)-heparin complexes: Potent sequence-specific inhibitors pf HIV-1 infection
58. Inhibition of leukaemia cell proliferation by receptor-mediated uptake of c-myc antisense oligodeoxynucleotides
59. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells
60. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine
61. Targeted delivery of antisense oligonucleotides by molecular conjugates
62. Enhanced cellular uptake of oligonucleotides by EGF receptor-mediated endocytosis in A549 cells
63. Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates
64. Uptake by macrophages of a biotyinylated oligo-α-deoxythymidylate by using mannosylated streptavidine
65. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood brain barrier in vivo
66. The spread and uptake pattern of intracerebrally administered oligonucleotides in nerve and glial cell populations of the rat brain
67. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration
68. Cellular distribution of phosphorothioate oligodeoxy nucleotides in normal rodent tissues
69. The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries